230 completed, 58 recruiting, 53 active not recruiting, 44 unknown. 439 Phase 3, 40 Phase 2.
Follow Blood Protein Disorders: new trials by email Literature Review of Blood Protein Disorders trials Research Report on Blood Protein Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 750 | 2027-02-01 | 2026-10-29 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma | Phase 3 | Not yet recruiting | Janssen Research & Development, LLC | 1000 | 2026-12-14 | 2026-10-29 |
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM) | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-09-24 | 2026-10-21 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Ramantamig, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1000 | 2026-09-09 | 2026-10-06 |
| Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma | Phase 3 | Recruiting | PrECOG, LLC. | 500 | 2026-09-01 | 2026-08-17 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | 248 | 2026-09-01 | 2026-07-31 |
| D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma | Phase 3 | Recruiting | Dana-Farber Cancer Institute | 720 | 2026-08-31 | 2026-10-09 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| GMMG-HD11/DSMM XXI/64007957MMY3010 Teclistamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Not yet recruiting | University of Heidelberg Medical Center | 399 | 2026-06-30 | 2026-06-26 |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT AZD0120, Daratumumab, Dexamethasone - Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-06-26 | 2026-08-14 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Recruiting | Hoffmann-La Roche | 380 | 2026-06-23 | 2026-10-13 |
| A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone - Myeloma Multiple | Phase 3 | Recruiting | Biocad | 390 | 2026-06-15 | 2026-08-03 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 255 | 2026-06-11 | 2026-09-17 |
Showing 20 of 439. Sign in to see all of them.
Multiple Myeloma (382) · Neoplasms, Plasma Cell (63) · Leukemia, Lymphocytic, Chronic, B-Cell (46) · Lymphoma, Non-Hodgkin (44) · Lymphoma (39) · Recurrence (39) · Hodgkin Disease (36) · Lymphoma, Follicular (34) · Lymphoma, Mantle-Cell (34) · Lymphoma, B-Cell, Marginal Zone (33) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (33) · Lymphoma, Large B-Cell, Diffuse (32) · Waldenstrom Macroglobulinemia (31) · Neoplasms (30) · Lymphoma, Large-Cell, Immunoblastic (29)
Hemic and Lymphatic Diseases (439) · Hematologic Diseases (430) · Immune System Diseases (424) · Immunoproliferative Disorders (406) · Lymphoproliferative Disorders (406) · Hemorrhagic Disorders (400) · Neoplasms by Histologic Type (400) · Cardiovascular Diseases (398) · Vascular Diseases (398) · Hemostatic Disorders (397) · Paraproteinemias (397) · Neoplasms (376) · Neoplasms, Plasma Cell (337) · Pathological Conditions, Signs and Symptoms (106)
Dexamethasone (192) · Bortezomib (107) · Lenalidomide (102) · daratumumab (60) · Thalidomide (49) · Cyclophosphamide (46) · Melphalan (46) · pomalidomide (46) · carfilzomib (32) · Calcium Dobesilate (30) · Prednisone (19) · Doxorubicin (16) · isatuximab (15) · Filgrastim (14) · elotuzumab (14)
Janssen Research & Development, LLC (26) · Celgene (18) · University of Arkansas (12) · Amgen (11) · GlaxoSmithKline (8) · National Cancer Institute (NCI) (8) · Alliance for Clinical Trials in Oncology (7) · Bristol-Myers Squibb (7) · Fondazione EMN Italy Onlus (7) · Fred Hutchinson Cancer Center (7) · Millennium Pharmaceuticals, Inc. (7) · PETHEMA Foundation (7) · AbbVie (6) · Pfizer (6) · SWOG Cancer Research Network (5)
United States (218) · Germany (121) · France (119) · United Kingdom (113) · Spain (109) · Italy (105) · Canada (99) · Australia (84) · Belgium (83) · Greece (81) · Poland (80) · Czechia (78) · China (72) · Israel (67) · Japan (66)
Robert Knight, MD (6) · Mario Boccadoro, MD (5) · Bart Barlogie, MD, PhD (3)
PMID 22689675, PMID 31221778, PMID 34289038, PMID 23897961, PMID 35985959, PMID 38023148, PMID 39229471, PMID 40501401, PMID 18799726, PMID 19901114, PMID 21160068, PMID 21228328, PMID 21273172, PMID 21791470, PMID 22674807, PMID 23065509, PMID 23233721, PMID 24117042, PMID 24335249, PMID 25261096, PMID 26771810, PMID 27002117, PMID 27738789, PMID 28293022, PMID 29675792, PMID 30561775, PMID 31221782, PMID 31231828, PMID 31248973, PMID 32499241, PMID 33006656, PMID 33151787, PMID 33513030, PMID 34269818, PMID 34587246, PMID 35876974, PMID 36108425, PMID 36130300, PMID 36818468, PMID 37990162, PMID 38031761, PMID 38048391, PMID 38048552, PMID 38062124, PMID 38573925, PMID 39293025, PMID 40763276, PMID 41627370, PMID 42085642, PMID 42212672
2023 (18), 2005 (8), 2014 (8), 2018 (7), 2025 (7), U10CA180820 (7), 2016 (6), U10CA021115 (6), 2015 (5), 2017 (5), 2008 (4), 2009 (3), 2019 (3), P30CA015083 (3), U10CA032102 (3)